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Abstract 
Objective:  It is unknown whether atrial fibrillation (AF) is associated with an 
increased risk of sudden cardiac death (SCD) in the general population. The 
objective of this study was to examine the association between incident AF and 
SCD in 2 population-based cohorts. 
Research Design & Methods: In the Atherosclerosis Risk in Communities 
(ARIC) Study, we analyzed data from 15439 participants (aged 4564 years at 
baseline, 55% women, and 27% black) obtained from baseline (19871989) 
through December 31, 2001. In the Cardiovascular Health Study (CHS), we 
analyzed data from 5479 participants (aged >65 years at baseline, 58% women, 
and 15% black) obtained from baseline (first cohort, 19891990; second cohort, 
19921993) through December 31, 2006. SCD was physician-adjudicated and 
was defined as a sudden, pulseless condition presumed due to a ventricular 
tachyarrhythmia in a previously stable individual. We used multivariable Cox 
proportional hazards models to assess the association between AF and SCD 
adjusting for age, sex, race, field center, and baseline cardiovascular risk factors. 
Results: In ARIC, 894 incident AF and 269 SCD events occurred during follow-
up (median, 13.1 years). In participants with and without AF, the crude incidence 
rates of SCD were 2.89 and 1.30 per 1000 person-years, respectively. The 
multivariable hazard ratio (HR) (95% confidence interval [CI]) of AF for SCD was 
3.26 (2.174.91), P<.001. In CHS, 1458 incident AF and 292 SCD events 
occurred during follow-up (median, 13.1 years). In participants with and without 
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AF, the crude incidence rates of SCD were 12.00 and 3.82 per 1000 person-
years, respectively. The multivariable HR (95% CI) of AF for SCD was 2.14 
(1.602.87), P<.001. The meta-analyzed HR (95% CI) of AF for SCD was 2.34 
(1.762.91), P<.001 
Conclusions:  Incident AF is associated with an increased risk of SCD in the 
general population. Additional research to identify predictors of SCD in patients 
with AF is warranted. 
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 Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and its 
prevalence is increasing over time.1, 2 AF is associated with an increased risk of 
stroke,3 heart failure,4 and death.5-7 The Framingham Heart Study reported that 
AF increases the risk of death by 1.5-fold in men and 1.9-fold in women.5 
Similarly, a study from Olmsted County, Minnesota showed that new-onset AF 
doubles the risk of mortality.6 More recently, the Women’s Health Study showed 
that the risk of all-cause death was doubled and cardiovascular death quadrupled 
by new-onset AF in initially healthy women.7  
 The common causes of death in individuals with AF in these studies were 
coronary heart disease (CHD) and stroke.5, 6 Sudden cardiac death (SCD) was 
not specifically reported.5-7 However, there is evidence from post-myocardial 
infarction (MI) or heart failure patients that AF is associated with an increased 
risk of SCD.8-10 It is unknown, however, whether AF increases the risk of SCD in 
the general population. 
 We hypothesized that incident AF is associated with an increased risk of 
SCD in the general population. We tested our hypothesis in the Atherosclerosis 
Risk in Communities (ARIC) Study, and Cardiovascular Health Study (CHS), 2 
large community-based cohort studies of cardiovascular disease in the USA.  
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Study Populations 
ARIC 
The ARIC cohort is a biracial sample, consisting of 15792 men and women, 
4564 years of age at baseline (19871989), from 4 communities in North 
Carolina, Mississippi, Minnesota, and Maryland.11 After the baseline examination, 
participants had 3 additional exams, the last in 19961998. In addition to study 
exams, ARIC participants have received annual follow-up calls since the first visit 
(>90% response rate) collecting information on general health and 
hospitalizations. The present study is based on data obtained from baseline 
(19871989) through December 31, 2001. We excluded participants with missing 
or uninterpretable ECG at baseline (n=243), with missing covariates (n=73), or 
with prevalent AF (n=37). The final analysis cohort consisted of 15439 ARIC 
participants. 
 
CHS 
The CHS is a cohort study of risk factors for CHD and stroke in older people.12 
Between 19891990, 4 field centers (North Carolina, California, Maryland, 
Pennsylvania) recruited a total of 5201 participants aged 65 years from 
Medicare eligibility lists. To enhance minority representation, during 19921993, 
687 African-American participants were recruited. The present study is based on 
data obtained from baseline (19891990 for first cohort and 19921993 for 
second cohort) through December 31, 2006. We excluded participants with 
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missing covariates (n=260) or with prevalent AF (n=149). The final analysis 
cohort consisted of 5479 CHS participants. 
 The CHS and ARIC study protocols were approved by the institutional 
review board of each participating center, and informed consent was obtained 
from each study participant. 
 
Ascertainment of Atrial Fibrillation 
ARIC 
AF diagnoses were obtained from ECGs at study visits and hospital discharge 
records.13 All ECG recordings automatically coded as AF were visually 
rechecked by a cardiologist to confirm the diagnosis.14 A trained abstractor 
obtained and recorded all International Classification of Diseases, Ninth Revision 
(ICD-9) hospital discharge diagnoses from each participant's hospitalizations 
reported in the annual follow-up interview. AF was defined as the presence of 
ICD-9 code 427.31 or 427.32 in the discharge codes. We confirmed 
approximately 90% of AF in a physician review of 125 discharge summaries 
indicating possible AF cases.13 
 
CHS 
AF was ascertained from ECGs and hospital discharge records. Participants 
were followed by annual study clinic examinations and interim phone contacts for 
10 years, with telephone contact every 6 months thereafter. A resting 12-lead 
ECG was performed at annual clinic visits through 1999. At each follow-up 
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contact, participants reported all hospitalizations since the last contact, and 
hospital discharge summaries and discharge ICD-9 codes were routinely 
obtained. In a review of discharge summaries and ECGs for 212 participants with 
discharge ICD-9 codes of 427.3, 427.31, or 427.32, 99% of potential AF cases 
were confirmed.15  
 
Outcomes Ascertainment 
In ARIC and CHS, comprehensive data were gathered on cardiovascular events 
and deaths from hospital records, interviews with physicians, next of kin and/or 
witnesses, death certificates, and autopsy reports, where available. Causes of 
death were adjudicated by respective ARIC and CHS events committees.  An 
independent review of CHD deaths16 was conducted by each cohort study to 
identify SCD events.  SCD was similarly defined in both ARIC and CHS:  a 
sudden pulseless condition presumed due to a ventricular tachyarrhythmia in a 
previously stable individual without evidence of a non-cardiac cause of cardiac 
arrest.  By definition, SCD cases could not have a life-threatening noncardiac 
comorbidity or be under hospice care.  All SCD cases in this analysis occurred 
out of the hospital or in the emergency room.  For unwitnessed deaths, the 
participant must have been seen within 24 hours of the arrest in a stable 
condition and without evidence of a noncardiac cause of cardiac arrest. 
In ARIC, all CHD deaths that occurred by December 31, 2001 were 
reviewed by a panel of 5 physicians to identify SCD events.  Each event was 
independently adjudicated by 2 physicians.  If there was a disagreement, a third 
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investigator reviewed the event to provide final classification.  After review of 
available data, CHD deaths were classified as definite sudden arrhythmic death, 
possible sudden arrhythmic death, not sudden arrhythmic death, or 
unclassifiable.17-19 For the present analysis, SCD was defined as definite or 
possible sudden arrhythmic deaths in ARIC.  
In CHS, all CHD deaths through December 31, 2006 were reviewed by a 
cardiologist (NS) in order to classify SCD cases. A blinded second physician 
review of a random sample of 70 of these death records showed an 88% inter-
reviewer agreement and κ=0.74 for SCD.  Both of these physicians also 
participated on the ARIC SCD review panel. After review of available data in 
CHS, CHD deaths were classified as definite, possible, or not SCD.  For the 
present analysis, the CHS SCD definition included both definite and possible 
SCDs. 
Non-SCD (NSCD) was defined as CHD death not meeting SCD criteria. 
 
Covariates  
Heart rate was determined from the resting 12-lead ECG. Body mass index was 
calculated as the ratio of weight in kilograms to height in meters squared. In 
ARIC and CHS, hypertension was defined as use of medication to treat high 
blood pressure, systolic blood pressure 140 mm Hg, and/or diastolic blood 
pressure 90 mm Hg. In ARIC, diabetes mellitus was defined as a self-reported 
physician’s diagnosis of diabetes, use of hypoglycemic medications, nonfasting 
serum glucose levels ≥200 mg/dL, or fasting serum glucose level ≥126 mg/dL. In 
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CHS, diabetes mellitus was defined as fasting serum glucose level ≥126 mg/dL 
or use of hypoglycemic medications. In ARIC, heart failure at baseline was 
defined as the reported use of medications to treat heart failure in the previous 2 
weeks or the presence of heart failure according to Gothenburg criteria;20 
incident heart failure at follow-up visits was defined as the presence of ICD-9-CM 
code 428 in any hospitalization or death certificate during follow-up.21 In CHS, 
heart failure confirmation required, in addition to physician diagnosis, one of the 
following: 1) documented heart failure symptoms (e.g., shortness of breath, 
fatigue, orthopnea, paroxysmal nocturnal dyspnea) and physical signs (e.g., 
edema, pulmonary rales, gallop rhythm) consistent with heart failure; 2) 
supporting clinical findings such as pulmonary edema on chest x-ray; or 3) 
therapy for heart failure, including diuretics, digitalis, angiotensin-converting 
enzyme inhibitors, or beta-blockers. In ARIC, prevalent coronary heart disease 
(CHD) was defined as physician-diagnosed CHD or the presence of a previous 
myocardial infarction (MI) by ECG. Incident CHD was adjudicated by the ARIC 
Morbidity and Mortality Classification Committee as previously described.16 In 
CHS, prevalent CHD was defined as a positive history for MI, coronary 
revascularization, or angina using information from self-report and hospitalization 
records. Questionnaires during study visits assessed self-reported smoking 
status (current, former, never) and smoking amount. Left ventricular hypertrophy 
was defined electrocardiographically based on Cornell criteria.22 Medication 
checks (digoxin, -blockers, and Class I and Class III anti-arrhythmic drugs) were 
performed during study visits. 
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Statistical Analysis 
We report means with standard deviations for continuous variables and counts 
with percentages for categorical variables. Person-years at risk were calculated 
from the date of baseline until the date of SCD/NSCD, other death, loss to follow-
up, or end of follow-up, whichever occurred first.  
To estimate the association of AF with risks of SCD and NSCD, we 
calculated hazard ratios (HRs) and 95% confidence intervals (CIs) using Cox 
proportional hazards model with AF as a time-dependent exposure variable. We 
ran 2 models: In Model 1, we adjusted for age, sex, race, and field center. In 
Model 2, we additionally adjusted for baseline covariates: heart rate, smoking 
status, body mass index, hypertension, diabetes mellitus, CHD, heart failure, 
ECG-based left ventricular hypertrophy, use of -blockers, use of digoxin, and 
use of anti-arrhythmic drugs. ARIC and CHS results were meta-analyzed using 
fixed effect analysis. We conducted 2 additional analyses using time-dependent 
covariates in ARIC. First, to account for confounding by covariates changing over 
time, we updated covariates to the time point just before ascertainment of AF, 
censoring, or SCD incidence, whichever occurred earlier. Second, to assess 
whether the association between AF and SCD is mediated by shared 
cardiovascular risk factors, we updated covariates to the end of follow-up. 
In addition, we conducted 2 sensitivity analyses. First, we restricted the 
definition of SCD to include only cases that were classified as definite sudden 
arrhythmic death (n=252 in ARIC and n=194 in CHS). Second, to control for 
possible confounding by left ventricular systolic dysfunction, we adjusted for left 
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ventricular fractional shortening on 2D-echocardiogram in ARIC participants at 
the Mississippi field center (n=2028, all black participants). In CHS, we adjusted 
for left ventricular ejection fraction (LVEF) (<45%, 4554%, 55%) on 2D-
echocardiogram (n=4816). The proportional hazards assumption was assessed 
with scaled Schoenfeld residuals for both graphical and numerical tests, time 
interaction terms, and inspection of log negative log survival curves. Modeling 
assumptions were not violated in any model.  
Statistical analysis of ARIC data was performed using SAS version 9.2 
(SAS Institute Inc., Cary, NC). Statistical analysis of CHS data was performed 
using R (R Foundation for Statistical Computing, Vienna, Austria) and STATA 
version 11.2 (StataCorp, College Station, TX). All P values reported were 2-
sided, and statistical significance threshold was chosen as 5%. 
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The cohort at risk for SCD in ARIC consisted of 8524 women and 6915 men 
aged 4564 years at baseline, and in CHS, 3189 women and 2290 men aged 
65 years at baseline. Of the 5479 participants in CHS, 4857 (88.6%) were from 
the first cohort and 622 (11.4%) were from the second cohort. During follow-up 
(median, 13.1; interquartile range [IQR], 12.413.9 years), 894 AF, 269 SCD, 
and 233 NSCD events occurred through 2001 in ARIC. During follow-up (median, 
13.1 years; IQR, 8.016.3 years), 1458 AF, 292 SCD, and 581 NSCD events 
occurred through 2006 in CHS.  
 
Atrial Fibrillation, Sudden Cardiac Death, and Nonsudden Cardiac Death 
ARIC 
Compared with participants without AF, those with incident AF had higher 
incidence rates of SCD and NSCD (Table 2). After adjustment for age, sex, race, 
and ARIC field center, AF was significantly associated with an increased risk of 
SCD and NSCD (Table 2, Model 1). Although additional adjustment for 
cardiovascular risk factors attenuated these risk estimates (Table 2, Model 2), 
the associations remained statistically significant. Overall, the presence of 
incident AF was associated with a tripling of the risk of SCD and doubling of the 
risk of NSCD.  
 To account for confounding by change of covariates over time, we 
adjusted the main analysis for time-dependent covariates by updating the 
covariates to the time point just before ascertainment of AF, censoring, or SCD 
incidence, whichever occurred earlier. We found that AF remained significantly 
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associated with SCD (HR, 2.87; 95% CI, 1.884.40); P<.001) (Table 3, Model 1). 
To investigate whether shared risk factors could mediate the association 
between AF and SCD, we conducted another time-dependent regression 
analysis by updating the covariates to the time point before end of follow-up. We 
found that even after adjusting for risk factors that are potentially on the causal 
pathway, AF was significantly associated with an increased risk of SCD (HR, 
2.03; 95% CI, 1.303.17; P=.002) (Table 3, Model 2). By contrast, AF was no 
longer significantly associated with NSCD after adjusting for risk factors that are 
potentially on the causal pathway (HR, 1.48; 95% CI, 0.942.34; P=.09) (Table 3, 
Model 2).   
 From sex-stratified analysis (Table 4), we found that the risk of SCD 
associated with AF in women (HR, 4.12; 95% CI, 1.918.90; P<.001) to be 
comparable with men (HR, 3.12; 95% CI, 1.935.04; P<.001) (P for interaction by 
sex=.60). However, race-stratified analysis showed that the risk of SCD 
associated with AF was higher in black (HR, 5.77; 95% CI, 2.9611.24; P<.001) 
than non-black participants (HR, 2.49; 95% CI, 1.494.17; P<.001) (P for 
interaction by race=.02) (Table 4). 
 We performed 2 sensitivity analyses. First, we restricted the analysis to 
only definite cases of SCD. The presence of AF was associated with a doubling 
of the risk of definite SCD (HR, 2.00; 95% CI, 1.223.28; P=.006) (Table 5). 
Second, to control for possible confounding by left ventricular systolic 
dysfunction, we restricted the analysis to participants at the ARIC Mississippi 
field center with fractional shortening measured by 2D-echocardiogram. Of 2028 
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participants in this sample, there were 53 AF and 30 SCD events through 2001. 
After adjustment for left ventricular fractional shortening, the HR (95% CI) of AF 
for SCD was 13.59 (4.2043.93), P<.001 (Table 6). 
 
CHS 
Incident AF was associated with a doubling of the risk of SCD in CHS (HR, 2.14; 
95% CI, (1.602.87), P<.001 (Table 2). The meta-analyzed HR (95% CI) of AF 
for SCD in ARIC and CHS was 2.34 (1.762.91), P<.001 (Table 2). Similar to 
ARIC, the risk of SCD associated with AF in women (HR, 2.50; 95% CI, 
1.573.96; P<.001) was comparable with that in men (HR, 2.01; 95% CI, 
1.382.92; P<.001) (P for interaction by sex=.34) (Table 4). In contrast to ARIC, 
we did not find an interaction of race with AF risk (P for interaction by race=.51) 
(Table 4).  
From sensitivity analysis, we found that AF was associated with a 
doubling of the risk of definite SCD in CHS (HR, 2.23; 95% CI, 1.553.21; 
P<.001) (Table 5). After adjustment for LVEF (<45%, 4554%, 55%) on 2D-
echocardiogram, AF was still associated with a significantly increased risk of 
SCD (HR, 2.06; 95% CI, 1.572.81; P<.001) (Table 7).  
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In 2 large population-based cohort studies in the USA including middle-aged and 
elderly individuals, we found that participants who developed incident AF during 
follow-up had an increased risk of SCD compared with participants who did not 
develop AF. Compared with participants without AF, the risk of SCD was tripled 
in participants with AF in ARIC and doubled in CHS. 
 Although prospective cohort studies have compellingly demonstrated an 
association between AF and increased risk of total and cardiovascular mortality,5-
7 none has shown that AF increases the risk of SCD specifically. However, AF 
may increase the risk of SCD in specific patient subgroups such as post-MI or 
heart failure patients.8-10 In the Trandolapril Cardiac Evaluation registry,8 
development of AF during hospitalization for MI was found to be associated with 
a 1.3-fold higher risk of SCD during subsequent follow-up. In another study of 
patients who were discharged after hospitalization for MI, AF development during 
hospitalization increased the risk of SCD by 2.7-fold during follow-up.10 In 
patients with severe heart failure, AF was found to be associated with a higher 
risk of SCD compared with patients without AFthe 1-year SCD-free survival in 
patients with AF was 69% as compared with 82% in patients without AF.9  
 To the best of our knowledge, the present study is the first to show that 
incident AF is associated with an increased risk of SCD in 2 independent 
population-based cohorts. This association was observed in men and women, 
blacks and non-blacks.  
Several mechanisms might explain our observation. First, AF may 
facilitate the induction of ventricular tachyarrhythmias. A rapid ventricular rate 
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during an atrial tachyarrhythmia will directly reduce ventricular refractoriness,23 
promoting ventricular tachyarrhythmias. In addition, the irregular rhythm of AF 
leads to short-long-short sequences that may be intrinsically proarrhythmic.24 
Evidence for AF facilitating induction of ventricular tachyarrhythmias comes from 
several sources. Somberg et al. reported from canine experiments that 
ventricular tachycardia (VT) was induced in 25 of 26 dogs by programmed 
electrical stimulation only in AF, and not in sinus rhythm.25 Similarly, in 5 patients 
with a history of AF and VT, VT was only inducible in 4 patients by programmed 
electrical stimulation when they were in AF, and not in sinus rhythm.25 The 
findings from these experiments suggest that AF may enhance myocardial 
vulnerability. Further evidence comes from patients who had been implanted with 
implantable cardioverter defibrillators (ICDs). Gronefeld et al. reported that AF is 
an independent predictor of ICD therapy for VT or ventricular fibrillation (VF).26 
Analysis of device-stored electrograms revealed a higher incidence of short-long-
short cycles preceding ventricular arrhythmias in AF compared with patients in 
sinus rhythm (50% versus 16%, P=.002).26 In another study of ICD recipients, 
8.6% of all VT/VF episodes were dual tachycardiaVT or VF occurring during 
and preceded by a paroxysm of atrial tachycardia or AF.27 Furthermore, the time 
to the next VT/VF episode is substantially prolonged in patients with dual 
tachycardia in whom the atrial tachyarrhythmia is terminated at the time of a 
ventricular therapy, as compared with those in whom the atrial tachyarrhythmia 
persists.27 Collectively, these observations suggest that atrial tachyarrhythmias 
may increase susceptibility to ventricular tachyarrhythmias.  
  18
Second, it is possible that the association between AF and SCD is 
mediated by shared risk factors such as CHD or heart failure. We note that AF is 
associated with an increased risk of NSCD; this association suggests that AF 
may also increase the risk of SCD through shared risk factors. To assess this 
possibility, we conducted a secondary analysis in ARIC by updating covariates to 
the end of follow-up. Although the association between AF and SCD was 
attenuated in this analysis, AF remained significantly associated with SCD after 
adjustment for factors potentially in the causal pathway. This observation 
suggests that the association between AF and SCD is only partially, and not 
completely, explained by the measured shared risk factors. By contrast, the 
association between AF and NSCD was no longer significant after adjustment for 
factors potentially in the causal pathway. 
 The principal strength of this study is the reproducible finding of a strong 
association between AF and SCD in 2 independent large population-based 
cohorts. Other strengths include the long follow-up, inclusion of non-white 
participants, extensive measurement of covariates, large number of AF cases, 
and physician-adjudication of all SCD cases. However, several limitations should 
be noted. First, incident AF was identified mostly from hospitalization discharges 
and we could not include asymptomatic AF or AF managed exclusively in an 
outpatient setting. However, we and others have previously shown that the 
validity of AF ascertainment using hospitalizations is acceptable,13, 15 that 
incidence rates of AF in ARIC are consistent with other population-based 
studies,13 and that the associations between genetic variants in the chromosome 
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4q25 locus and AFextremely specific for AF riskin ARIC and CHS are similar to 
other studies with a more rigorous ascertainment of AF.28 Second, we could 
adjust for left ventricular systolic function in only a subgroup of the ARIC cohort. 
The small sample size for this subgroup analysis was reflected in the wide 
confidence intervals. However, even after this adjustment, the association 
between AF and SCD remained statistically significant. Moreover, after 
adjustment for LVEF in CHS, AF remained a significant risk factor for SCD.  
 In conclusion, in 2 large, population based-cohorts of middle-aged and 
elderly individuals, incident AF independently increases the risk of SCD. This 
finding should be confirmed in additional studies, and if so, it adds to our evolving 
understanding that AF is not a benign conditionnot only does it predispose to 
stroke, heart failure, and death, but AF per se may increase risk of death from 
ventricular tachyarrhythmias. The latter is potentially preventable, and to this end, 
additional research to identify predictors of SCD in patients with AF is much 
needed. 
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Table 1. Baseline Characteristics According to Atrial Fibrillation Status, Atherosclerosis Risk in Communities (ARIC) Study and  
Cardiovascular Health Study (CHS)a 
 
 
 ARIC Incident AF through 2001, ARIC CHS Incident AF through 2006, CHSb 
 Total sample 
(n=15439) 
No 
(n=14545) 
Yes 
(n=894) 
Total sample 
(n=5479) 
No 
(n=4021) 
Yes 
(n=1458) 
Age, mean (SD), y 54.2 (5.8) 54.0 (5.7) 57.5 (5.3) 72.7 (5.5) 72.5 (5.5) 73.4 (5.6) 
Female  8524 (55.2) 8147 (56.0) 377 (42.2) 3189 (58.2) 2396 (59.6) 793 (54.4) 
Black race 4107 (26.6) 3945 (27.1) 162 (18.1) 845 (15.4) 689 (17.1) 156 (10.7) 
Current cigarette smoking 4044 (26.2) 3752 (25.8) 284 (31.8) 658 (12.0) 502 (12.5) 156 (10.7) 
Body mass index,  mean (SD) 
(kg/m2) 
27.7 (5.4) 27.6 (5.3) 28.9 (6.1) 26.7 (4.7) 26.6 (4.7) 26.9 (4.8) 
Heart rate, mean (SD), (bpm)c 66.3 (10.3) 66.2 (10.2) 66.7 (11.3) 65.0 (11.4) 65.3 (11.6) 64.1 (11.0) 
ECG-based LVH  338 (2.2) 292 (2.0) 46 (5.2) 280 (5.1) 205 (5.1) 75 (5.1) 
Diabetes  1816 (11.8) 1633 (11.2) 183 (20.5) 1609 (29.4) 1161 (28.9) 448 (30.7) 
Hypertension  5353 (34.7) 4892 (33.6) 461 (51.6) 3207 (58.5) 2275 (56.6) 932 (63.9) 
Coronary heart disease  737 (4.8) 626 (4.3) 111 (12.4) 1049 (19.1) 697 (17.3) 352 (24.1) 
Heart failure  716 (4.6) 613 (4.2) 103 (11.5) 211 (3.1) 129 (3.2) 82 (5.6) 
Use of beta-blockers  1611 (10.4) 1415 (9.7) 196 (21.9) 695 (12.7) 482 (12.0) 213 (14.6) 
Use of anti-arrhythmics  115 (0.7) 80 (0.6) 35 (3.9) 172 (3.1) 91 (2.3) 81 (5.6) 
 
Abbreviations: AF, atrial fibrillation; LVH, left ventricular hypertrophy based on Cornell criteria 
aData are presented as No. (%) of participants unless otherwise stated 
bThe second CHS cohort had by design 3 years shorter follow-up than the first CHS cohort 
cHeart rate was determined based on 12-lead ECG at baseline 
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Table 2. Risk of Sudden Cardiac Death and Nonsudden Cardiac Death by Atrial Fibrillation Status, Atherosclerosis Risk in Communities Study (ARIC) and 
Cardiovascular Health Study (CHS) 
 
Abbreviations: AF, atrial fibrillation; CI, confidence interval 
aPer 1000 person-years of follow-up 
bCox proportional hazards model adjusted for age, sex, race, and field center  
cModel 1 additionally adjusted for baseline covariates: heart rate, smoking status, body mass index, hypertension, diabetes, coronary heart disease, heart failure, 
ECG-based left ventricular hypertrophy, use of beta-blockers, use of digoxin, and use of anti-arrhythmic drugs. In CHS, Model 2 was not adjusted for use of 
digoxin 
  Incident AF through 2001, 
ARIC 
 Incident AF through 2006, CHS  Meta-analysis 
  No Yes P Value No Yes P 
Value 
HR (95% CI) P Value P Value 
for 
heterogen
eity 
Sudden Cardiac Death           
   Number of events  238 31  225 67      
   Person-years  183086 10719  58877 5582      
   Crude incidence rate  
   (95%  CI)a 
 1.30 
(1.141.47) 
2.89 
(2.004.05) 
 3.82 
(3.354.35) 
12.00 
(9.4515.25) 
     
   Hazard ratio (95% CI) Model 
1b 
1 [Referent] 5.40 
(3.638.04) 
<.001 1 [Referent] 2.51 
(1.883.33) 
<.001 2.79 
(2.103.48) 
<.001 .02 
 Model 
2c 
1 [Referent] 3.26 
(2.174.91) 
<.001 1 [Referent] 2.14 
(1.602.87) 
<.001 2.34 
(1.762.91) 
<.001 .15 
Nonsudden Cardiac 
Death 
          
   Number of events  189 44  379 202     
   Person-years  183086 10719  58877 5582     
   Crude incidence rate  
   (95%  CI)a 
 1.03 
(0.891.19) 
4.10 
(3.025.46) 
 6.44 
(5.827.11) 
36.19 
(31.5241.54) 
    
   Hazard ratio (95% CI) Model 
1b 
1 [Referent] 4.66 
(3.126.95) 
<.001 1 [Referent] 3.55 
(2.974.25) 
<.001 3.66 
(3.054.27) 
<.001 .28 
 Model 
2c 
1 [Referent] 2.43 
(1.603.71) 
<.001 1 [Referent] 3.10 
(2.583.72) 
<.001 2.95 
(2.453.45) 
<.001 .27 
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Table 3. Risk of Sudden Cardiac Death and Nonsudden Cardiac Death by Atrial 
Fibrillation Using Time-Dependent Covariates, Atherosclerosis Risk in Communities 
Study 
 
Abbreviations: AF, atrial fibrillation; CI, confidence interval 
aCox proportional hazards model adjusted for age, sex, race, ARIC field center and time-
dependent covariates: heart rate, smoking status, body mass index, hypertension, 
diabetes, coronary heart disease, heart failure, ECG-based left ventricular hypertrophy, 
use of beta-blockers, use of digoxin, and use of anti-arrhythmic drugs. Time-dependent 
covariates were updated to the time point just before ascertainment of AF, censoring, or 
SCD incidence, whichever occurred earlier.  
 
bCox proportional hazards model adjusted for the same covariates as in Model 1. 
However, time-dependent covariates were updated to end of follow-up. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Incident AF through 2001  
  No  Yes  P Value 
Sudden Cardiac Death     
   Hazard ratio (95% CI) Model 1a 1 [Referent] 2.87 (1.884.40) <.001 
 Model 2b 1 [Referent] 2.03 (1.303.17) .002 
Nonsudden Cardiac 
Death 
    
   Hazard ratio (95% CI) Model 1a 1 [Referent] 2.05 (1.333.17) .001 
 Model 2b 1 [Referent] 1.48 (0.942.34) .09 
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Table 4. Sex- and Race-Stratified Risks of Sudden Cardiac Death by Atrial Fibrillation Status, Atherosclerosis Risk in Communities Study (ARIC) and 
Cardiovascular Health Study (CHS) 
 
 
  Incident AF through 2001, ARIC  Incident AF through 2006, 
CHS 
 Meta-Analysis 
  No  
 
Yes  
 
P Value No Yes P Value HR (95% CI) 
 
P Value P Value 
for 
hetero-
geneity 
By sex           
Female           
  Number of SCD events  83 9  93 26     
         Person-years ` 103852 4561  36831 2973     
         Incidence rate(95%  CI)c  0.80 
(0.640.99) 
1.97 
(0.973.60) 
 2.53 
(2.063.09) 
8.74 (5.95–
12.84) 
    
         Hazard ratio (95% CI) Model 1a 1 [Referent] 6.63 
(3.1314.00) 
<.001 1 [Referent] 2.86 (1.82–
4.48) 
<.001 3.07 
(1.784.36) 
<.001 .19 
 Model 2b 1 [Referent] 4.12 
(1.918.90) 
<.001 1 [Referent] 2.50 (1.57–
3.96) 
<.001 2.67 
(1.543.80) 
<.001 .39 
           
Male           
  Number of SCD events  155 22  132 41     
         Person-years  79235 6158  22046 2609     
         Incidence rate(95% CI)c  1.96 
(1.672.28) 
3.57 
(2.305.31) 
 5.99 
(5.057.10) 
15.71 
(11.5721.3
4) 
    
         Hazard ratio (95% CI) Model 1a 1 [Referent] 5.01 
(3.138.00) 
<.001 1 [Referent] 2.35 (1.62–
3.40) 
<.001 2.66 
(1.833.50) 
<.001 .04 
 Model 2b 1 [Referent] 3.12 
(1.935.04) 
<.001 1 [Referent] 2.01 (1.38–
2.92) 
<.001 2.23 
(1.542.92) 
<.001 .21 
           
By race           
Non-Black           
   Number of SCD events  136 20  175 61     
          Person-years  135086 8879  50528 5031     
         
 
 1.01 
(0.851.19) 
2.25 
(1.423.41) 
 3.46 
(2.994.02) 
12.12 (9.43–
15.58) 
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Abbreviations: AF, atrial fibrillation; CI, confidence interval; SCD, sudden cardiac death 
aCox proportional hazards model adjusted for age, sex, race, and field center  
bModel 1 additionally adjusted for baseline covariates: heart rate, smoking status, body mass index, hypertension, diabetes, coronary 
heart disease, heart failure, ECG-based left ventricular hypertrophy, use of beta-blockers, use of digoxin, and use of anti-arrhythmic 
drugs. In CHS, Model 2 was not adjusted for digoxin 
cPer 1000 person-years of follow-up 
 
 
 
 
 
 
          Incidence rate(95% CI)c 
        
 
          Hazard ratio (95% CI) 
Model 1a 1 [Referent] 4.38 
(2.667.23) 
<.001 1 [Referent] 2.61 (1.92–
3.54) 
<.001 2.81 
(2.043.57) 
<.001 .15 
 Model 2b 1 [Referent] 2.49 
(1.494.17) 
<.001 1 [Referent] 2.16 (1.58–
2.95) 
<.001 2.23 
(1.622.84) 
<.001 .67 
 
 
Black 
          
  
  Number of SCD events 
 102 11  50 6     
         Person-years  48000 1840  8349 551     
         Incidence rate(95% CI)c  2.13 
(1.742.57) 
5.98 
(3.1710.35) 
 5.99 (4.53–
7.90) 
10.89 (4.89–
24.24) 
    
         Hazard ratio (95% CI) Model 1a 1 [Referent] 8.39 
(4.4215.91) 
<.001 1 [Referent] 1.83 (0.77–
4.34) 
.17 2.41 
(0.704.11) 
.006 .03 
 Model 2b 1 [Referent] 5.77 
(2.9611.24) 
<.001 1 [Referent] 2.23 (0.89–
5.54) 
.09 3.08 
(1.055.11) 
.003 .14 
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Table 5. Risk of Definite Sudden Cardiac Death by Atrial Fibrillation Status, Atherosclerosis Risk in Communities Study (ARIC)  
and Cardiovascular Health Study (CHS) 
 
  
 
Abbreviations: AF, atrial fibrillation; CI, confidence interval 
aPer 1000 person-years of follow-up 
bCox proportional hazards model adjusted for age, sex, race, and field center  
cModel 1 additionally adjusted for baseline covariates: heart rate, smoking status, body mass index, 
hypertension, diabetes, coronary heart disease, heart failure, ECG-based left ventricular hypertrophy, use of 
beta-blockers, use of digoxin, and use of anti-arrhythmic drugs. In CHS, Model 2 was not adjusted for digoxin 
 
  Incident AF through 
2001, ARIC 
 Incident AF through 2006, 
CHS 
 Meta-Analysis 
  No Yes P 
Value 
No Yes P 
Value 
HR 
(95% 
CI) 
P 
Value 
P for  
hetero- 
geneity 
Definite Sudden 
Cardiac Death 
          
   Number of events  226 26  151 43     
   Person-years  183086 10719  58811 5648     
   Crude incidence rate  
   (95% CI)a 
 1.23 
(1.081.40)
2.43 
(1.623.50)
 2.57 
(2.193.01) 
7.61 
(5.6510.27) 
    
    Hazard ratio (95% 
CI) 
Model 1b 1 
[Referent] 
3.36 
(2.085.45)
<.001 1 [Referent] 2.72  
(1.90–3.89) 
<.001 2.89 
(2.033.
74) 
<.001 .52 
 Model 2c 1 
[Referent] 
2.00 
(1.223.28)
.006 1 [Referent] 2.23 
(1.553.21) 
<.001 2.14 
(1.492.
79) 
<.001 .74 
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Table 6. Risk of Sudden Cardiac Death by Atrial Fibrillation Status with Adjustment  
for Left Ventricular Fractional Shortening, Atherosclerosis Risk in Communities 
Study, Jackson Field Center, Mississippi 
 
Abbreviations: AF, atrial fibrillation; CI, confidence interval 
aPer 1000 person-years of follow-up, adjusted for age, sex, and race 
bCox proportional hazards model adjusted for baseline age, sex, heart failure, coronary 
heart disease, and use of beta-blockers 
cModel 1 additionally adjusted for left ventricular fractional shortening at Visit 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Incident AF through 2001  
  No Yes P Value 
Sudden Cardiac Death     
   Number of events  24 6  
   Person-years  25765 656  
   Incidence rate (95% CI)a  0.93 (0.611.36) 9.15 (3.8018.86)  
    Hazard ratio (95% CI) Model 1b 1 [Referent] 14.91 (4.7147.22) <.001 
 Model 2c 1 [Referent] 13.59 (4.2043.93) <.001 
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Table 7. Risk of Sudden Cardiac Death by Atrial Fibrillation Status with Adjustment for 
Left Ventricular Ejection Fraction, Cardiovascular Health Study 
 
Abbreviations: AF, atrial fibrillation; CI, confidence interval 
aPer 1000 person-years of follow-up, adjusted for age, sex, and race 
bCox proportional hazards model adjusted for age, sex, race, and field center  
cModel 1 additionally adjusted for baseline covariates: heart rate, smoking status, body 
mass index, hypertension, diabetes, coronary heart disease, heart failure, ECG-based 
left ventricular hypertrophy, use of beta-blockers, and use of anti-arrhythmic drugs 
dModel 2 additionally adjusted for left ventricular ejection fraction 
((<45%, 4554%, 55%) on 2D-echocardiogram) 
 
 
 
 
 
 
 
 
  Incident AF through 2006  
  No Yes P Value 
Sudden Cardiac Death     
   Number of events  191 60  
   Person-years  52633 5107  
   Incidence rate (95% CI)a  3.63 (3.15–4.18) 11.75 (9.12–15.13)  
    Hazard ratio (95% CI) Model 1b 1 [Referent] 2.49 (1.84–3.38) <.001 
 Model 2c 1 [Referent] 2.08 (1.53–2.83) <.001 
 Model 3d 1 [Referent] 2.06 (1.51–2.81) <.001 
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